跳至主要内容
临床试验/EUCTR2013-002562-39-NL
EUCTR2013-002562-39-NL进行中(未招募)不适用

An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.

Institut de Recherches Internationales Servier (IRIS)0 个研究点开始时间: 2013年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Male or female, aged = 18 years
  • - Weight = 45 kg and = 125 kg
  • - For subjects with reproductive potential, a willingness to use highly effective contraceptive measures, and for female subjects a negative serum pregnancy test
  • - Probable or definite Schnitzler syndrome according to Strasbourg criteria.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 2
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3

排除标准

  • - Differential diagnoses other than Schnitzler syndrome,
  • - Any prior treatment with systemic alkylating agents within the previous 6 months prior to selection,
  • - Active TB disease,
  • - History of severe allergic or anaphylactic reactions to monoclonal antibodies,
  • - History of malignancy within 5 years prior to selection,
  • - Known immunodeficiency,
  • - Infectious disease,
  • - Any live (attenuated) vaccine within 3 months prior to selection,
  • - Pregnancy, breastfeeding or possibility to become pregnant during the study

研究者

发起方
Institut de Recherches Internationales Servier (IRIS)

相似试验